Immunogenic multistage recombinant protein vaccine confers partial protection against experimental toxoplasmosis mimicking natural infection in murine model

Basit Öğe Kaydı
dc.contributor.authorGedik Y.
dc.contributor.authorGülçe Iz S.
dc.contributor.authorCan H.
dc.contributor.authorDe?irmenci Döşkaya A.
dc.contributor.authorIsmet Delilo?lu Gürhan S.
dc.contributor.authorGürüz Y.
dc.contributor.authorDöşkaya M.
dc.date.accessioned2019-10-26T21:19:52Z
dc.date.available2019-10-26T21:19:52Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractToxoplasma gondii is a protozoan parasite that can infect warm-blooded animals including humans. Vaccination studies mostly use tachyzoite specific proteins however in natural route of infection, toxoplasmosis initiates with tissue cysts (bradyzoites) or oocysts (sporozoites) and thereafter stage conversion takes place where the tachyzoites take action and cause acute infection continues with tachyzoites. Despite this knowledge, challenging models used in the vaccination studies prefer administration of tissue cyst forming strains intraperitoneally or subcutaneously instead of oral administration which is the natural route of infection. In the present study, a multivalent adjuvanted recombinant protein vaccine that contains bradyzoite specific BAG1 and tachyzoite specific GRA1 protein and controls were administered to female Swiss Webster outbred mice. Humoral and cellular immune responses were analyzed by Rec-ELISA, Western blot, and flow cytometry. Mice were infected orally with T. gondii PRU strain tissue cysts using feeding needle to mimic the natural route of infection. 40 days after challenging microscopy and Real Time PCR were performed to determine the protection level. Analysis of sera obtained from vaccinated mice showed strong anti-BAG1 and anti-GRA1 IgG responses. The IgG2a response was significantly higher (P < 0.0001) and the ratio of CD8 + T lymphocytes secreting IFN-? almost doubled compared to PBS control which are indicative of protection against toxoplasmosis. The amount of tissue cysts in vaccinated group was reduced 10.5% compared to control group. To generate a protective vaccine against toxoplasmosis, multistage vaccines and usage of challenging models mimicking natural route of infection are critical cornerstones. In this study, we generated a BAG1 and GRA1 multistage vaccine that induced strong immune response in which the protection was not at anticipated level. In addition, the murine model was orally challenged with tissue cysts to mimic natural route of infection. © 2015 Published by Elsevier Ltd.en_US
dc.description.sponsorship110S200en_US
dc.description.sponsorshipThis study was supported by the Grant given by The Scientific and Technological Research Council of Turkey (110S200) to Y.G. T. gondii PRU strain was kindly obtained from Prof. Marie-Laure Dardé. The authors would like to acknowledge AtaFen Inc., Veterinary Vaccine Production Plant and their team for their generous help through the project and Prof. Wolfgang Bohne for providing BAG1 DNA backbone. The topic of the study was presented in 23rd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) in Berlin, Germany, 2013. The authors state that they have no conflict of interest. --en_US
dc.identifier.doi10.1016/j.trivac.2015.11.002
dc.identifier.endpage23en_US
dc.identifier.issn1879-4378
dc.identifier.issn1879-4378en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage15en_US
dc.identifier.urihttps://doi.org/10.1016/j.trivac.2015.11.002
dc.identifier.urihttps://hdl.handle.net/11454/16701
dc.identifier.volume5en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofTrials in Vaccinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBAG1en_US
dc.subjectGRA1en_US
dc.subjectRecombinant protein vaccineen_US
dc.subjectToxoplasma gondiien_US
dc.titleImmunogenic multistage recombinant protein vaccine confers partial protection against experimental toxoplasmosis mimicking natural infection in murine modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu